Immunocore (IMCR)
(Delayed Data from NSDQ)
$31.09 USD
+0.20 (0.65%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.09 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.09 USD
+0.20 (0.65%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.09 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
Zacks News
DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study
by Zacks Equity Research
The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
by Zacks Equity Research
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study
by Zacks Equity Research
ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.
The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly
by Zacks Equity Research
United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.
3 Drug Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA
by Zacks Equity Research
bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.
Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe
by Zacks Equity Research
Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the European Medicines Agency.
The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant
by Zacks Equity Research
Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.
Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth
by Zacks Equity Research
Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.
4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
by Kinjel Shah
Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.
Can Immunocore Holdings PLC Sponsored ADR (IMCR) Climb 27% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 27.1% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BEAM Up as FDA Lifts Clinical Hold on the IND for BEAM-201
by Zacks Equity Research
The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. Stock up.
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study
by Zacks Equity Research
Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.
Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
by Zacks Equity Research
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics
by Zacks Equity Research
BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs targeting immune modulation in cancer and other diseases. Stock up.
Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
by Zacks Equity Research
Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal
by Zacks Equity Research
Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the primary and key secondary endpoints. Shares rise.
Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.
Immunocore Holdings PLC Sponsored ADR (IMCR) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now
by Zacks Equity Research
Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
by Zacks Equity Research
uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation
by Zacks Equity Research
Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
by Zacks Equity Research
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.
How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 28%
by Zacks Equity Research
The consensus price target hints at a 27.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.